CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
Status:
Recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the
current Chinese pediatric and adolescent high-risk ALCL and compared with our historical
data.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Cancer Group, China
Collaborators:
1st Affiliated Hospital of Zhengzhou University Nanjing Children's Hospital Qilu Hospital of Shandong University Shanghai Children's Medical Center Tianjin Cancer Hospital West China Second University Hospital Xiangya Hospital